Health utilities and quality of life in individuals with tuberous sclerosis complex (TSC) who experience epileptic seizures: A web-based survey.


Journal

Epilepsy & behavior : E&B
ISSN: 1525-5069
Titre abrégé: Epilepsy Behav
Pays: United States
ID NLM: 100892858

Informations de publication

Date de publication:
03 2019
Historique:
received: 18 09 2018
revised: 18 10 2018
accepted: 19 11 2018
pubmed: 29 1 2019
medline: 20 5 2020
entrez: 29 1 2019
Statut: ppublish

Résumé

Individuals with tuberous sclerosis complex (TSC) experience a wide range of health impacts, including epileptic seizures, negatively impacting their health-related quality of life (HRQoL). Health state utility values (HSUVs) are index values representing HRQoL and are used as key inputs for health economic analyses. Such data are currently very limited in the TSC population. The objective of this study was to generate HSUVs for TSC health states, defined by the number and type of seizures experienced in the previous week, and to compare with UK normative values. This cross-sectional study involved 186 participants (individuals with TSC = 61, caregivers reporting for individuals with TSC = 125) from Europe and North America who completed a web-based survey. Participants completed the [EuroQol - 5 dimensions - 3 levels] (self-report version for individuals with TSC or proxy version 1 for caregivers). The mean age of individuals with TSC was 27.3 years (self-reported: 41.3 years, caregiver-reported: 20.5 years); 56% were males. Most individuals with TSC (71%) reported experiencing between one and ten seizures in the week prior to participating in the study. The most frequently reported type of seizure was focal: simple partial (50%). Across all participants (combined self-report and caregiver-report), the mean HSUV was 0.474 (95% confidence interval [CI]: 0.424-0.524), significantly lower than the UK norm (0.856, 95%CI: 0.848-0.864) [1]. Mean HSUV and HRQoL scores were consistently lower when reported by caregivers than when self-reported by individuals with TSC (HSUV = 0.351 vs. 0.727). This is in part because caregivers reported for individuals with TSC who experienced more frequent and severe seizures than those who were able to self-report. HSUVs incrementally decreased with the experience of more frequent (1-5 per week: HSUV = 0.666 vs. >20: HSUV = 0.290) and more severe seizures (focal: simple partial: HSUV = 0.450 vs. generalized: convulsive: HSUV = 0.194). The HRQoL and HSUV index scores indicate substantial impairment among individuals with TSC; HSUVs were shown to decrease considerably with increases in seizure frequency or seizure severity, indicating that more burdensome seizure health states are associated with poorer HRQoL.

Identifiants

pubmed: 30690322
pii: S1525-5050(18)30743-1
doi: 10.1016/j.yebeh.2018.11.021
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

213-220

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Auteurs

Theo Tritton (T)

Adelphi Values, Adelphi Mill, Bollington, Cheshire SK10 5JB, United Kingdom. Electronic address: theo.tritton@adelphivalues.com.

Bryan Bennett (B)

Adelphi Values, Adelphi Mill, Bollington, Cheshire SK10 5JB, United Kingdom.

Elaine Brohan (E)

Adelphi Values, Adelphi Mill, Bollington, Cheshire SK10 5JB, United Kingdom.

Laura Grant (L)

Adelphi Values, Adelphi Mill, Bollington, Cheshire SK10 5JB, United Kingdom.

Alison Cooper (A)

Tuberous Sclerosis Association, CAN Mezzanine 32-36 Loman Street, London SE1 0EH, United Kingdom.

Carla Fladrowski (C)

European Tuberous Sclerosis Association, In den Birken, 30, 45711 Dattein, Germany.

Cathy Evanochko (C)

Tuberous Sclerosis Canada Sclérose Tubéreuse, 35057 Essa Road RO, Barrie, ON L4N 5Z2, Canada.

Maureen Neary (M)

Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936-1080, United States.

João Vieira (J)

Novartis Pharmaceuticals UK Limited, 200 Frimley Business Park, GB-Frimley/Camberley, Surrey GU16 7SR, United Kingdom.

Viviana Buffa (V)

Novartis Pharmaceuticals UK Limited, 200 Frimley Business Park, GB-Frimley/Camberley, Surrey GU16 7SR, United Kingdom.

Chris Kingswood (C)

St George's Hospital, Blackshaw Road, London SW17 0QT, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH